Merus N.V. Doses First Patient In Phase 2 Trial Of Petosemtamab For Second-Line Metastatic Colorectal Cancer; Biclonics Therapy Targets EGFR And LGR5
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. has dosed the first patient in its Phase 2 trial of Petosemtamab for second-line metastatic colorectal cancer. The Biclonics therapy targets EGFR and LGR5.
July 08, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus N.V. has initiated a Phase 2 trial for Petosemtamab, targeting EGFR and LGR5 in second-line metastatic colorectal cancer. This milestone could positively impact the stock price.
The initiation of a Phase 2 trial is a significant milestone for biotech companies, often leading to positive investor sentiment. The specific targeting of EGFR and LGR5 in metastatic colorectal cancer could indicate potential efficacy, further boosting confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100